Stanford, California 94305

  • Head and Neck Cancers


The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Study summary:

The endpoints of the study are 1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance. 2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.


Inclusion Criteria: - Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck. - Able to sign a Stanford IRB approved consent form Exclusion criteria: - Refuse or unable to sign an IRB approved consent form. - Refuse to be contacted in the future for follow up.



Primary Contact:

Principal Investigator
Quynh-Thu Le
Stanford University

Rachel Freiberg

Backup Contact:


Location Contact:

Stanford, California 94305
United States

Rachel Freiberg
Phone: 650-725-0438

Site Status: Recruiting

Data Source:

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.